Optinose downgraded to Neutral from Buy at H.C. Wainwright

Written by Emily J. Thompson, Senior Investment Analyst

OPTN%

Updated: Mar 21 2025

0mins

Downgrade of Optinose: H.C. Wainwright has downgraded Optinose from Buy to Neutral with a price target of $9 following the announcement of its acquisition by Paratek Pharmaceuticals.
Acquisition Details: Paratek Pharmaceuticals will acquire Optinose for $9 per share upfront, along with contingent value rights that could add up to $5 per share.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Optinose downgraded to Neutral from Buy at H.C. Wainwright

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Micron Technology to Acquire Powerchip's P5 Fab for $1.8 Billion

Micron Technology Acquires Powerchip's P5 Fab for $1.8 Billion

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch